Cargando…
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal ant...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119589/ https://www.ncbi.nlm.nih.gov/pubmed/15234813 http://dx.doi.org/10.1016/j.jviromet.2004.04.009 |
_version_ | 1783514796751060992 |
---|---|
author | Berry, Jody D Jones, Steven Drebot, Michael A Andonov, Anton Sabara, Marta Yuan, Xin Y Weingartl, Hana Fernando, Lisa Marszal, Peter Gren, Jason Nicolas, Brigitte Andonova, Maya Ranada, Francesca Gubbins, Michael J Ball, T.Blake Kitching, Paul Li, Yan Kabani, Amin Plummer, Frank |
author_facet | Berry, Jody D Jones, Steven Drebot, Michael A Andonov, Anton Sabara, Marta Yuan, Xin Y Weingartl, Hana Fernando, Lisa Marszal, Peter Gren, Jason Nicolas, Brigitte Andonova, Maya Ranada, Francesca Gubbins, Michael J Ball, T.Blake Kitching, Paul Li, Yan Kabani, Amin Plummer, Frank |
author_sort | Berry, Jody D |
collection | PubMed |
description | There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development. |
format | Online Article Text |
id | pubmed-7119589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71195892020-04-08 Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Berry, Jody D Jones, Steven Drebot, Michael A Andonov, Anton Sabara, Marta Yuan, Xin Y Weingartl, Hana Fernando, Lisa Marszal, Peter Gren, Jason Nicolas, Brigitte Andonova, Maya Ranada, Francesca Gubbins, Michael J Ball, T.Blake Kitching, Paul Li, Yan Kabani, Amin Plummer, Frank J Virol Methods Article There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development. Elsevier B.V. 2004-09-01 2004-06-05 /pmc/articles/PMC7119589/ /pubmed/15234813 http://dx.doi.org/10.1016/j.jviromet.2004.04.009 Text en Copyright © 2004 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Berry, Jody D Jones, Steven Drebot, Michael A Andonov, Anton Sabara, Marta Yuan, Xin Y Weingartl, Hana Fernando, Lisa Marszal, Peter Gren, Jason Nicolas, Brigitte Andonova, Maya Ranada, Francesca Gubbins, Michael J Ball, T.Blake Kitching, Paul Li, Yan Kabani, Amin Plummer, Frank Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title_full | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title_fullStr | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title_full_unstemmed | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title_short | Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus |
title_sort | development and characterisation of neutralising monoclonal antibody to the sars-coronavirus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119589/ https://www.ncbi.nlm.nih.gov/pubmed/15234813 http://dx.doi.org/10.1016/j.jviromet.2004.04.009 |
work_keys_str_mv | AT berryjodyd developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT jonessteven developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT drebotmichaela developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT andonovanton developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT sabaramarta developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT yuanxiny developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT weingartlhana developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT fernandolisa developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT marszalpeter developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT grenjason developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT nicolasbrigitte developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT andonovamaya developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT ranadafrancesca developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT gubbinsmichaelj developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT balltblake developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT kitchingpaul developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT liyan developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT kabaniamin developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus AT plummerfrank developmentandcharacterisationofneutralisingmonoclonalantibodytothesarscoronavirus |